1887

Science and Money: Problems and Solutions

    Author: David B. Resnik1
    VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709
    AUTHOR AND ARTICLE INFORMATION AUTHOR AND ARTICLE INFORMATION
    • Published 15 December 2014
    • Corresponding author. Mailing address: National Institute of Environmental Health Sciences, National Institutes of Health, 111 Alexander Drive, Box 12233, Mail Drop CU 03, Research Triangle Park, NC 27709. Phone: 919-541-5658. Fax: 919-541-9854. E-mail: [email protected].
    • ©2014 Author(s). Published by the American Society for Microbiology.
    Source: J. Microbiol. Biol. Educ. December 2014 vol. 15 no. 2 159-161. doi:10.1128/jmbe.v15i2.792
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • HTML
    24.72 Kb
  • PDF
    148.68 Kb
  • XML

    Abstract:

    Because science is a business replete with many different types of financial interests, eliminating or even drastically reducing them is not a realistic option. The best approach to dealing with financial interests in research is to implement policies designed to minimize or mitigate their impact on scientific integrity.

References & Citations

1. Battelle. 2013 2014 Global R&D funding forecast. R&DMagazine. [Online.] http://www.battelle.org/docs/tpp/2014_global_rd_funding_forecast.pdf?sfvrsn=4
2. Bekelman JE, Li Y, Gross CP 2003 Scope and impact of financial conflicts of interest in biomedical research: a systematic review JAMA 289 454 465 10.1001/jama.289.4.454 12533125 http://dx.doi.org/10.1001/jama.289.4.454
3. Elliott KC 2011 Is a little pollution good for you? Oxford University Press New York NY 10.1093/acprof:oso/9780199755622.001.0001 http://dx.doi.org/10.1093/acprof:oso/9780199755622.001.0001
4. Friedberg M, Saffran B, Stinson T, Nelson W, Bennett C 1999 Evaluation of conflict of interest in new drugs use in oncology JAMA 282 1453 1457 10.1001/jama.282.15.1453 10535436 http://dx.doi.org/10.1001/jama.282.15.1453
5. Krimsky S 2003 Science in the private interest Rowman and Littlefield Lanham, MD
6. Lexchin J, Bero LA, Djulbegovic B, Clark O 2003 Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 1167 1170 10.1136/bmj.326.7400.1167 12775614 156458 http://dx.doi.org/10.1136/bmj.326.7400.1167
7. McGarity TO, Wagner WE 2012 Bending science Harvard University Press Cambridge, MA
8. Michaels D 2008 Doubt is their product Oxford University Press New York NY
9. Resnik DB 2007 The price of truth: how money affects the norms of science Oxford University Press New York NY 10.1093/acprof:oso/9780195309782.001.0001 http://dx.doi.org/10.1093/acprof:oso/9780195309782.001.0001
10. Resnik DB, Elliott KC 2013 Taking financial relationships into account when assessing research Account Res 20 184 205 10.1080/08989621.2013.788383 23672544 3954632 http://dx.doi.org/10.1080/08989621.2013.788383
11. Ridker PM, Torres J 2006 Reported outcomes in major cardiovascular clinical trials funded by for-profit and notfor-profit organizations: 2000–2005 JAMA 295 2270 2274 10.1001/jama.295.19.2270 16705108 http://dx.doi.org/10.1001/jama.295.19.2270
12. Shamoo AE, Resnik DB 2014 Responsible conduct of research 3rd ed Oxford University Press New York NY
13. Sismondo S 2008 Pharmaceutical company funding and its consequences: a qualitative systematic review Contemp Clin Trials 29 109 113 10.1016/j.cct.2007.08.001 http://dx.doi.org/10.1016/j.cct.2007.08.001
14. Stelfox H, Chua G, O’Rourke K, Detsky A 1998 Conflict of interest in the debate over calcium channel antagonists N Engl J Med 338 101 106 10.1056/NEJM199801083380206 9420342 http://dx.doi.org/10.1056/NEJM199801083380206

Supplemental Material

No supplementary material available for this content.

Loading

Article metrics loading...

/content/journal/jmbe/10.1128/jmbe.v15i2.792
2014-12-15
2020-11-30

Abstract:

Because science is a business replete with many different types of financial interests, eliminating or even drastically reducing them is not a realistic option. The best approach to dealing with financial interests in research is to implement policies designed to minimize or mitigate their impact on scientific integrity.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

/deliver/fulltext/jmbe/15/2/jmbe-15-159.xml.a.html?itemId=/content/journal/jmbe/10.1128/jmbe.v15i2.792&mimeType=html&fmt=ahah

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error